The CCL20-CCR6 Axis in Cancer Progression

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Jul 26

PMID 32707869

Citations 120

Authors

Suguru Kadomoto

Kouji Izumi

Atsushi Mizokami

Affiliations

Soon will be listed here.

Abstract

Chemokines, which are basic proteins that exert their effects via G protein-coupled receptors and a subset of the cytokine family, are mediators deeply involved in leukocyte migration during an inflammatory reaction. Chemokine (C-C motif) ligand 20 (CCL20), also known as macrophage inflammatory protein (MIP)-3α, liver activation regulated chemokine (LARC), and Exodus-1, is a small protein that is physiologically expressed in the liver, colon, and skin, is involved in tissue inflammation and homeostasis, and has a specific receptor chemokine receptor 6 (CCR6). The CCL20-CCR6 axis has long been known to be involved in inflammatory and infectious diseases, such as rheumatoid arthritis and human immunodeficiency virus infections. Recently, however, reports have shown that the CCL20-CCR6 axis is associated with several cancers, including hepatocellular carcinoma, colorectal cancer, breast cancer, pancreatic cancer, cervical cancer, and kidney cancer. The CCL20-CCR6 axis promotes cancer progression directly by enhancing migration and proliferation of cancer cells and indirectly by remodeling the tumor microenvironment through immune cell control. The present article reviewed the role of the CCL20-CCR6 axis in cancer progression and its potential as a therapeutic target.

Citing Articles

MIP-3-Alpha and MIP-3-Beta as Early Predictors of Pneumonia in Polytraumatized Patients.

Wollner G, Hruska F, Ettel P, Weichhart T, Koenig F, Negrin L Lung. 2025; 203(1):44.

PMID: 40074940 PMC: 11903586. DOI: 10.1007/s00408-025-00799-2.

Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancer.

Kim H, Jung S, Bang Y, Kim J, Kim H, Lee H J Immunother Cancer. 2025; 13(3).

PMID: 40032602 PMC: 11877152. DOI: 10.1136/jitc-2024-010455.

Prostate Cancer: De-regulated Circular RNAs With Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Genomics Proteomics. 2025; 22(2):136-165.

PMID: 39993805 PMC: 11880926. DOI: 10.21873/cgp.20494.

Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche.

Mondal J, Zhang J, Qing F, Li S, Kumar D, Huse J Nat Commun. 2025; 16(1):1378.

PMID: 39910049 PMC: 11799300. DOI: 10.1038/s41467-025-56347-2.

Disulfidptosis-related immune patterns predict prognosis and characterize the tumor microenvironment in oral squamous cell carcinoma.

Wu X, Liu B, Deng S, Xiong T, Dai L, Cheng B BMC Oral Health. 2025; 25(1):180.

PMID: 39894803 PMC: 11789412. DOI: 10.1186/s12903-024-05279-2.

References

Yang X, Ran R, Du J, Qiu Z, Cui L, Jiang X . CCL20 is overexpressed in hepatocellular carcinoma with bile duct tumor thrombus and correlates negatively with surgical outcome. Int J Clin Exp Pathol. 2020; 11(8):3977-3983. PMC: 6962792. View

Han G, Wu D, Yang Y, Li Z, Zhang J, Li C . CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine. 2015; 76(2):163-169. DOI: 10.1016/j.cyto.2015.05.009. View

Hieshima K, Imai T, Opdenakker G, Van Damme J, Kusuda J, Tei H . Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem. 1997; 272(9):5846-53. DOI: 10.1074/jbc.272.9.5846. View

Inozume T, Hanada K, Wang Q, Yang J . IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother. 2009; 32(2):109-17. PMC: 7386431. DOI: 10.1097/CJI.0b013e31819302da. View

Loberg R, Ying C, Craig M, Yan L, Snyder L, Pienta K . CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007; 9(7):556-62. PMC: 1939930. DOI: 10.1593/neo.07307. View

Atreya R, Neurath M . Chemokines in inflammatory bowel diseases. Dig Dis. 2010; 28(3):386-94. DOI: 10.1159/000320392. View

Zhang X, Hu Z, Meng A, Duan G, Zhao Q, Yang J . Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma. Oncol Lett. 2017; 14(6):8183-8189. PMC: 5727607. DOI: 10.3892/ol.2017.7253. View

Omata M, Lesmana L, Tateishi R, Chen P, Lin S, Yoshida H . Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4(2):439-74. PMC: 2900561. DOI: 10.1007/s12072-010-9165-7. View

Chen W, Qin Y, Wang D, Zhou L, Liu Y, Chen S . CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018; 16(7):e2005869. PMC: 6082578. DOI: 10.1371/journal.pbio.2005869. View

10.

Chen K, Lin S, Zhou L, Xie H, Zhou W, Taki-Eldin A . Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 2011; 6(9):e24671. PMC: 3173477. DOI: 10.1371/journal.pone.0024671. View

11.

Baba M, Imai T, Nishimura M, Kakizaki M, Takagi S, Hieshima K . Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem. 1997; 272(23):14893-8. DOI: 10.1074/jbc.272.23.14893. View

12.

Najjar Y, Rayman P, Jia X, Pavicic Jr P, Rini B, Tannenbaum C . Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2016; 23(9):2346-2355. PMC: 5411325. DOI: 10.1158/1078-0432.CCR-15-1823. View

13.

Bell D, Chomarat P, Broyles D, Netto G, Harb G, Lebecque S . In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 1999; 190(10):1417-26. PMC: 2195690. DOI: 10.1084/jem.190.10.1417. View

14.

Chen D, Jiang R, Mao C, Shi L, Wang S, Yu L . Chemokine/chemokine receptor interactions contribute to the accumulation of Th17 cells in patients with esophageal squamous cell carcinoma. Hum Immunol. 2012; 73(11):1068-72. DOI: 10.1016/j.humimm.2012.07.333. View

15.

Kapur N, Mir H, Clark Iii C, Krishnamurti U, Beech D, Lillard J . CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer. 2016; 114(12):1343-51. PMC: 4984452. DOI: 10.1038/bjc.2016.113. View

16.

Williams I . CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis. Ann N Y Acad Sci. 2006; 1072:52-61. DOI: 10.1196/annals.1326.036. View

17.

Davies L, Jenkins S, Allen J, Taylor P . Tissue-resident macrophages. Nat Immunol. 2013; 14(10):986-95. PMC: 4045180. DOI: 10.1038/ni.2705. View

18.

Griffith J, Sokol C, Luster A . Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014; 32:659-702. DOI: 10.1146/annurev-immunol-032713-120145. View

19.

McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

20.

Hromas R, Gray P, Chantry D, Godiska R, Krathwohl M, Fife K . Cloning and characterization of exodus, a novel beta-chemokine. Blood. 1997; 89(9):3315-22. View